Depot formulations to sustain periocular drug delivery to the posterior eye segment

被引：38

作者：

Agban, Yosra ^{[1
]}

Thakur, Sachin S. ^{[1
]}

Mugisho, Odunayo O. ^{[1
]}

Rupenthal, Ilva D. ^{[1
]}

机构：

[1] Univ Auckland, Fac Med & Hlth Sci, New Zealand Natl Eye Ctr, Dept Ophthalmol,Buchanan Ocular Therapeut Unit, Private Bag 92019, Auckland 1142, New Zealand

来源：

DRUG DISCOVERY TODAY | 2019年 / 24卷 / 08期

关键词：

BIODEGRADABLE INTRASCLERAL IMPLANT; INTRAVITREAL CONTROLLED-RELEASE; RETINAL-PIGMENT EPITHELIUM; TRANSSCLERAL DELIVERY; TRIAMCINOLONE ACETONIDE; HUMAN SCLERA; SUBCONJUNCTIVAL INJECTION; ANECORTAVE ACETATE; POLYMERIC DEVICE; NANO-PARTICLES;

D O I：

10.1016/j.drudis.2019.03.023

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The periocular space is a promising alternative route for the delivery of drugs to the posterior eye segment, especially when treating conditions in the outer ocular layers. In this review, we discuss the different periocular routes as well as the physiological barriers and elimination mechanisms limiting drug bioavailability at the back of the eye. We then highlight various types of depot formulations, including particulate delivery systems, semisolid formulations, and implants, used to increase the contact time with the ocular tissues. With the additional advantage of sustaining drug release, such depot formulations could enhance periocular drug delivery to the posterior eye segment.

引用

页码：1458 / 1469

页数：12

共 111 条

[81]

Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99

[82] The suprachoroidal pathways: a new drug delivery route to the back of the eye [J].

Rai, Uma Do J. P. ;

Young, Simon A. ;

Thrimawithana, Thilini R. ;

Abdelkader, Hamdy ;

Alani, Adam W. G. ;

Pierscionek, Barbara ;

Alany, Raid G. .

DRUG DISCOVERY TODAY, 2015, 20 (04) :491-495

[83]

RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857

[84] Barrier analysis of periocular drug delivery to the posterior segment [J].

Ranta, Veli-Pekka ;

Mannermaa, Eliisa ;

Lummepuro, Kirsi ;

Subrizi, Astrid ;

Laukkanen, Antti ;

Antopolsky, Maxim ;

Murtomaki, Lasse ;

Hornof, Margit ;

Urtti, Arto .

JOURNAL OF CONTROLLED RELEASE, 2010, 148 (01) :42-48

[85] Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration [J].

Regillo, Carl D. ;

D'Amico, Donald J. ;

Mieler, William F. ;

Schneebaum, Cary ;

Beasley, Cliff H. ;

Sullins, Gregory T. .

SURVEY OF OPHTHALMOLOGY, 2007, 52 :S70-S78

[86] Sustained Subconjunctival Protein Delivery Using a Thermosetting Gel Delivery System [J].

Rieke, Erin R. ;

Amaral, Juan ;

Becerra, S. Patricia ;

Lutz, Robert J. .

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 26 (01) :55-64

[87] A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide [J].

Robinson, MR ;

Lee, SS ;

Kim, H ;

Kim, S ;

Lutz, RJ ;

Galban, C ;

Bungay, PM ;

Yuan, P ;

Wang, NS ;

Kim, J ;

Csaky, KG .

EXPERIMENTAL EYE RESEARCH, 2006, 82 (03) :479-487

[88] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview [J].

Schinkel, Alfred H. ;

Jonker, Johan W. .

ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 :138-153

[89] Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl-Δ2-1,3,4,-thiadiazoline-2-sulfonamide [J].

Schoenwald, RD ;

Tandon, V ;

Wurster, DE ;

Barfknecht, CF .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 46 (01) :39-50

[90] CYTOCHROME-P450, DRUG-METABOLIZING-ENZYMES AND ARACHIDONIC-ACID METABOLISM IN BOVINE OCULAR-TISSUES [J].

SCHWARTZMAN, ML ;

MASFERRER, J ;

DUNN, MW ;

MCGIFF, JC ;

ABRAHAM, NG .

CURRENT EYE RESEARCH, 1987, 6 (04) :623-630

← 3 4 5 6 7 8 9 10 11 12 →